These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 11842385

  • 1. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD.
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD.
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA.
    J Clin Oncol; 2005 Feb 20; 23(6):1088-95. PubMed ID: 15657401
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI.
    J Clin Oncol; 2001 Jan 15; 19(2):389-97. PubMed ID: 11208830
    [Abstract] [Full Text] [Related]

  • 10. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF, Seymour JF, Hicks RJ, Turner JH.
    J Clin Oncol; 2006 Sep 20; 24(27):4418-25. PubMed ID: 16940276
    [Abstract] [Full Text] [Related]

  • 11. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA, Minnie Pearl Cancer Research Network.
    J Clin Oncol; 2003 May 01; 21(9):1746-51. PubMed ID: 12721250
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [Abstract] [Full Text] [Related]

  • 14. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
    Davis TA, Maloney DG, Grillo-López AJ, White CA, Williams ME, Weiner GJ, Dowden S, Levy R.
    Clin Cancer Res; 2000 Jul 01; 6(7):2644-52. PubMed ID: 10914705
    [Abstract] [Full Text] [Related]

  • 15. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.
    J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411
    [Abstract] [Full Text] [Related]

  • 16. Rituximab: ongoing and future clinical development.
    Grillo-López AJ, Hedrick E, Rashford M, Benyunes M.
    Semin Oncol; 2002 Feb 01; 29(1 Suppl 2):105-12. PubMed ID: 11842397
    [Abstract] [Full Text] [Related]

  • 17. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V.
    Ann Oncol; 1999 Jun 01; 10(6):655-61. PubMed ID: 10442187
    [Abstract] [Full Text] [Related]

  • 18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS, Perry CM.
    Drugs; 2006 Jun 01; 66(6):791-820. PubMed ID: 16706552
    [Abstract] [Full Text] [Related]

  • 19. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W.
    Dtsch Med Wochenschr; 2002 Oct 25; 127(43):2253-8. PubMed ID: 12397539
    [Abstract] [Full Text] [Related]

  • 20. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA.
    J Clin Oncol; 2005 Feb 20; 23(6):1103-8. PubMed ID: 15657404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.